摘要
中国感染艾滋病病毒(HIV)的患者总数仍在逐年增加,因抗病毒需持久治疗,更需要有效安全抗病毒新药问世。2018年中国批准的捷扶康?为国内首个基于丙酚替诺福韦(TAF)的HIV感染完整治疗方案复方单片剂,其骨干成分之一TAF是一种新型替诺福韦前体药物。相较于目前广泛使用的富马酸替诺福韦二吡呋酯(TDF),TAF药理学特性更为优越。国际临床研究证实,基于TAF的治疗方案在初治HIV感染者中显示出与既往基于TDF方案相当的疗效和较优越的肾脏、骨骼安全性,在达到病毒学抑制的患者中,换用基于TAF的维持治疗方案可改善患者骨密度和肾功能指标;现有真实世界数据与临床研究结果一致。可以预期,基于TAF的治疗方案将为HIV感染者,特别是合并肾损伤或骨病及肾脏或骨并发症风险较高的患者人群提供更好的治疗选择,有助于满足我国HIV感染者的治疗需求。
The number of people living with HIV infection is still rising in China, which needs safe and effective treatment options. In 2018, Genvoya? became the first tenofovir alafenamide(TAF)-based, complete, single-tablet HIV regimen approved in China. TAF is a new tenofovir prodrug with more favorable pharmacological characteristics than the currently widely used tenofovir disoproxil fumarate(TDF). International clinical studies have shown that in treatment-na?ve HIV-infected patients, TAF-based treatment exhibited comparable efficacy and better renal and bone safety profiles than the existing TDF-based regimens. In virologically suppressed patients, switching to TAF-based regimens could improve patients’ bone density and renal function markers. The real-world effectiveness and safety of TAF-based treatment observed thus far were consistent with clinical study results. TAF-based regimens are better, which can help meet the treatment needs of Chinese patients with HIV infection, especially for the patients with concomitant renal impairment/bone disease and patients at higher risk for developing renal/bone complications.
作者
李凌华
蔡卫平
LI Linghua;CAI Weiping(Guangzhou Eighth People’s Hospital,Guangzhou 510060,China)
出处
《中国艾滋病性病》
CAS
CSCD
北大核心
2020年第1期97-102,共6页
Chinese Journal of Aids & STD
基金
国家“十三五”科技重大专项(2017ZX10202101-003)
2018年度广州市健康医疗协同创新重大专项(201803040002).
